- Home
- ATOS vs STHO Comparison
ATOS vs STHO Comparison
Compare ATOS & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- STHO
- Stock Information
- Founded
- ATOS 2009
- STHO N/A
- Country
- ATOS United States
- STHO United States
- Employees
- ATOS N/A
- STHO N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- STHO Real Estate
- Sector
- ATOS Health Care
- STHO Real Estate
- Exchange
- ATOS Nasdaq
- STHO Nasdaq
- Market Cap
- ATOS 114.5M
- STHO 117.1M
- IPO Year
- ATOS 2012
- STHO N/A
- Fundamental
- Price
- ATOS $0.80
- STHO $8.85
- Analyst Decision
- ATOS Strong Buy
- STHO
- Analyst Count
- ATOS 3
- STHO 0
- Target Price
- ATOS $7.00
- STHO N/A
- AVG Volume (30 Days)
- ATOS 678.1K
- STHO 64.7K
- Earning Date
- ATOS 03-31-2025
- STHO 02-18-2025
- Dividend Yield
- ATOS N/A
- STHO N/A
- EPS Growth
- ATOS N/A
- STHO N/A
- EPS
- ATOS N/A
- STHO N/A
- Revenue
- ATOS N/A
- STHO $113,297,000.00
- Revenue This Year
- ATOS N/A
- STHO N/A
- Revenue Next Year
- ATOS N/A
- STHO N/A
- P/E Ratio
- ATOS N/A
- STHO N/A
- Revenue Growth
- ATOS N/A
- STHO N/A
- 52 Week Low
- ATOS $0.72
- STHO $7.96
- 52 Week High
- ATOS $2.31
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- ATOS 41.00
- STHO 49.86
- Support Level
- ATOS $0.79
- STHO $8.59
- Resistance Level
- ATOS $0.89
- STHO $8.96
- Average True Range (ATR)
- ATOS 0.05
- STHO 0.30
- MACD
- ATOS 0.01
- STHO 0.08
- Stochastic Oscillator
- ATOS 25.14
- STHO 86.47
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.